榮昌生物(688331.SH)IPO定價為48元/股 3月22日申購
格隆匯3月20日丨榮昌生物(688331.SH)發佈首次公開發行股票並在科創板上市發行公吿,在剔除無效報價以及最高報價部分後,發行人與聯席主承銷商根據網下發行詢價報價情況,綜合評估公司合理投資價值、可比公司二級市場估值水平、所屬行業二級市場估值水平等方面,充分考慮網下投資者有效申購倍數、市場情況、募集資金需求及承銷風險等因素,協商確定此次發行價格為48元/股。
網下申購日及起止時間為2022年3月22日(T日)9:30-15:00,網上申購日及起止時間為2022年3月22日9:30-11:30、13:00-15:00。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.